Capital to Fund Clinical Trials and Corporate Operations
Inventiva plans to allocate most of the proceeds to fund clinical trials, particularly for therapies targeting metabolic dysfunction-associated steatohepatitis (MASH), a liver disease. Remaining funds will support working capital and general corporate purposes.
The company, a clinical-stage biopharma specialist, focuses on oral therapies for MASH, a progressive liver condition.
Strategic Investor Participation
Samsara BioCapital L.P., which holds about 5.7% of Inventiva’s share capital, has subscribed to roughly five million ADSs, contributing around $20 million to the offering.
By expanding the offering, Inventiva positions itself to accelerate research timelines while ensuring the financial flexibility needed to navigate late-stage clinical development — a critical phase for any biopharma seeking to bring innovative therapies to market.
